PubMed
Prolonged stimulation of growth hormone (GH) secretion after a single administration of CJC-1295
Teichman SL, Neale A, Lawrence B, et al. J Clin Endocrinol Metab. 2006
Compare
CJC-1295 vs Pentosan Polysulfate
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
CJC-1295
33 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 96% · Mixed 4% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
138
Sleep
138
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Fatigue
2
Headache
2
Water retention
1
Self-reported dose per injection
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.1–3 mg
0.1–0.2 mg
24
0.2–0.4 mg
39
0.4–0.6 mg
23
1–2 mg
31
2–3 mg
21
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 48 days · Based on 25 repeat reporters
Pentosan Polysulfate
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 0% · Mixed 17% · Unfavorable overall 83%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Digestive upset
6
Self-reported dose per injection
Median bucket: 0–25 mcg · Most common: 0–25 mcg
Reports cluster around 0–25 mcg
0–25
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Sources (7)
Published sources linked on the CJC-1295 and Pentosan Polysulfate wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
- Wiki study page →Source
ClinicalTrials.gov
CJC-1295 growth hormone studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
FDA Drug Label
ELMIRON (pentosan polysulfate sodium) — Prescribing Information
Janssen Pharmaceuticals. FDA Drug Label. 1996
- Wiki study page →Source
PubMed
Pentosan polysulfate sodium for knee osteoarthritis: systematic review
Bannuru RR, Osani MC, Vaysbrot EE, et al. Osteoarthritis Cartilage. 2020
- Wiki study page →Source
PubMed
New therapeutic strategies in osteoarthritis
Siddiq MAB, Oo WM, Hunter DJ. Joint bone spine. 2024
- Wiki study page →Source
PubMed
The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment
Ghosh P. Seminars in arthritis and rheumatism. 1999